Pharmacogenomics of antidepressant treatment effects

Julio Licinio, Ma Li Wong

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

LanguageEnglish
Pages63-71
Number of pages9
JournalDialogues in Clinical Neuroscience
Volume13
Issue number1
Publication statusPublished - 2011
Externally publishedYes

Keywords

  • Adverse reaction
  • Antidepressant
  • Depression
  • Drug target
  • Genetics
  • Pharmacogenomics
  • Serotonin Transporter (Slc6a4)
  • Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Licinio, Julio ; Wong, Ma Li. / Pharmacogenomics of antidepressant treatment effects. In: Dialogues in Clinical Neuroscience. 2011 ; Vol. 13, No. 1. pp. 63-71.
@article{7725d88ccdbd4b21a8f0011a8d7a1a5a,
title = "Pharmacogenomics of antidepressant treatment effects",
abstract = "There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.",
keywords = "Adverse reaction, Antidepressant, Depression, Drug target, Genetics, Pharmacogenomics, Serotonin Transporter (Slc6a4), Therapeutics",
author = "Julio Licinio and Wong, {Ma Li}",
year = "2011",
language = "English",
volume = "13",
pages = "63--71",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "1",

}

Licinio, J & Wong, ML 2011, 'Pharmacogenomics of antidepressant treatment effects', Dialogues in Clinical Neuroscience, vol. 13, no. 1, pp. 63-71.

Pharmacogenomics of antidepressant treatment effects. / Licinio, Julio; Wong, Ma Li.

In: Dialogues in Clinical Neuroscience, Vol. 13, No. 1, 2011, p. 63-71.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacogenomics of antidepressant treatment effects

AU - Licinio, Julio

AU - Wong, Ma Li

PY - 2011

Y1 - 2011

N2 - There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

AB - There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

KW - Adverse reaction

KW - Antidepressant

KW - Depression

KW - Drug target

KW - Genetics

KW - Pharmacogenomics

KW - Serotonin Transporter (Slc6a4)

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=79955796641&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 63

EP - 71

JO - Dialogues in Clinical Neuroscience

T2 - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 1

ER -